Formulation for percutaneous administration for treating disturb

Details Formulation for percutaneous administration for treating disturb Formulation for percutaneous administration for treating disturb

1996-11-15

1998-06-23

Webman, Edward J.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

424448, 424486, 604307, 5147724, A61K 970, A61K 4732, A61M 3700

Patent

active

057702217

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to a formulation for percutaneous administration for treating disturbance in micturition. More particularly, the present invention relates to a formulation for percutaneous administration effective for treating disturbance in micturition, such as urinary incontinence, difficulty of micturition, pollakisuria, pain on micturition and the like.


BACKGROUND ART

The disturbance in micturition is a generic term concerning the disorders of micturition conduct, and it includes urinary incontinence, difficulty of micturition, pollakisuria, pain on micturition and the like.
Among them, the urinary incontinence is a disorder of micturition which may be occurred in any age groups, and it has been increasingly given attention by the general public in recent years. In particular, the incidence of urinary incontinence in aged people is very high, it has been still increasing, and it becomes a big problem before the coming aged people society. Moreover, without regard to whether aged or not, there are very many women suffering from urinary incontinence, and thus it can not be overlooked.
There have been many attempts to treat the disturbances in micturition such as urinary incontinence, and many peroral-administration type medicine for treating disturbance in micturition have already been on the market.
However, since the patients suffering from severe cerebrovascular disease bringing disturbance in micturition or the patients after operations of various tumors and the like, need times when they are bedridden, the administrations of the peroral-type medicine which must be administered every constant hours, are difficult in many cases.
On the other hand, in order to avoid the extreme decrease in bioavailability due to the so-called "first-pass effect" of liver in the case of the peroral administration of medicines, and in order to prevent the increase in incidence of side-effects due to the temporary increase in the concentration in blood, there have been many attempts to form various medicines into formulation for percutaneous administration as a method for slow-releasing medicines. The medicine for treating disturbance in micturition is expected to be administered as a formulation for percutaneous administration.
The Japanese Un-examined Patent Publication No.Hei 4-266821 describes that the medicines for treating disturbance in micturition such as terodiline, oxybutynin, propiverine, flavoxate are formed into percutaneous absorption-type therapeutic formulations.
In addition, the Japanese Un-examined Patent Publication No.Hei 4-273818 describes that terodiline, oxybutynin and the like are formed into percutaneous absorption-type therapeutic formulations such as patches and solutions.
However, in these publications, the drug stability which is important in forming formulations, and the physical stability, the irritativeness to skin and the constant releasability of the formulations are not sufficiently investigated. For example, although in Examples in the above Japanese Un-examined Patent Publication No.Hei 4-266821, terodiline and oxybutynin are used as hydrochlorides, and aqueous bases are prepared to be investigated, a sufficient drug stability can not be expected due to the mutual action of many additives and water contained in the formulation. The number of times of application of drugs is expected to be small, such as one time/day or one time/two days, by the above reasons and the like. However, in the case of aqueous bases, the number of times of application need to be large, because the adhesive stability at the time of long period adhesion is poor.
Further, it is the same in the above Japanese Un-Examined Patent Publication No.Hei 4-273718, the stability of drug and the irritativeness to skin and the like of the formulation are poor, and it can not be deemed that the formulation meets the requirements of commercialization.
Therefore, the purpose of the invention is to provide a formulation for percutaneous administration for treating disturbance in micturition, wh

REFERENCES:
patent: 4262003 (1981-04-01), Urquhart et al.
patent: 4623346 (1986-11-01), von Bittera et al.
patent: 4793337 (1988-12-01), Freeman et al.
patent: 4938759 (1990-07-01), Enscore et al.
patent: 5059189 (1991-10-01), Cilento et al.
patent: 5411740 (1995-05-01), Lee et al.
patent: 5480648 (1996-01-01), Wendel et al.
patent: 5503843 (1996-04-01), Santus et al.
patent: 5508038 (1996-04-01), Wang et al.

Affiliated with

Also associated with

Rating

Formulation for percutaneous administration for treating disturb does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation for percutaneous administration for treating disturb, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation for percutaneous administration for treating disturb will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1392586